Unleash Long-Term Growth with This Top-Quality Biotech Stock
Investors of All Ages and Experience Can Thrive in the Stock Market with Confidence
The stock market can be a daunting place for even the most seasoned investors, but there are tools available to help guide decision-making and increase confidence. One such tool is the Zacks Style Scores, which provide indicators for three widely-followed investing types: value, growth, and momentum. These scores can be used to find winning stocks based on an individual’s preferred investment methodology.
The Power of Growth Investing
Growth-oriented investors are concerned with a stock’s future prospects and the overall financial health and strength of a company. They focus on characteristics such as projected and historical earnings, sales, and cash flow to identify stocks that will experience sustainable growth over time. The Growth Style Score is an essential tool for these investors, analyzing key metrics to find companies poised for success.
Qiagen: A Leader in Molecular Diagnostics Solutions
QIAGEN N.V., based in Venlo, the Netherlands, is a global leader in molecular diagnostics solutions and sample preparation technologies. With over 500 proprietary products and automated solutions for sample collection, QGEN has developed a comprehensive portfolio that caters to various needs in the healthcare industry.
Growth Fundamentals and Strong Financials
QIAGEN boasts a Growth Style Score of B and VGM Score of A, with a Zacks Rank #2 (Buy) rating. The company’s bottom-line is projected to rise 6.9% year-over-year for 2025, while Wall Street anticipates its top line to improve by 4%. Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, increasing the Zacks Consensus Estimate by $0.07 to $2.33 per share. QGEN also boasts an average earnings surprise of 4.9%.
Cash Flow Growth and Expansion
In addition to its impressive growth fundamentals, Qiagen is cash rich with a history of generating cash flow growth of 3.3%. The company is expected to report cash flow expansion of 0% in 2025, indicating stability and predictability.
Conclusion
Qiagen should be on investors’ short lists due to its impressive growth fundamentals, good Zacks Rank, and strong Growth and VGM Style Scores. With a proven track record of innovation and financial strength, QGEN presents an attractive opportunity for those seeking sustainable growth in the stock market.
